No Truqap déjà vu in triple-negative breast cancer

Endocrine receptor-positive breast cancer carrying PIK3CA/AKT1/PTEN alterations provided a way into the market for AstraZeneca’s Truqap last November, but the trick won’t be repeated in triple-negative disease. Astra today said the AKT inhibitor’s chemo combo CAPItello-290 trial, in front-line triple-negative breast cancer patients, failed to show an overall survival benefit versus chemo alone. There was no signal either in the overall population or in a subgroup of patients with tumours harbouring PIK3CA/AKT1/PTEN alterations. That mirrors the earlier failure of Roche’s now discontinued AKT inhibitor ipatasertib in the Ipatunity-170 trial. Ipatasertib also failed in the ER-positive breast cancer population in which Truqap got approved, as well as in castration-sensitive prostate cancer, where Truqap’s CAPItello-280 study is due to end in 2026. Before then Truqap could see another clinical catalyst: CAPItello-281, in first-line PTEN-altered hormone-sensitive prostate cancer, is due to complete this October, six months earlier than prior estimates.

Selected Truqap studies

Source: OncologyPipeline.